Uniqure NV
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
Yellow, because the company’s fate hinges on a single event — the FDA’s decision on AMT-130 by May 1, 2027 — without a documented threat to its substance. Against green: apart from the one-time HEMGENIX sale in 2021, uniQure has never been profitable, a revenue base of its own is missing, the application rests on twelve high-dose patients versus an external control, and the agency has changed its stance on that data twice. Clearly against red: $810.3 million in cash against $178.0 million in operating cash outflow in 2025 means about four and a half years of runway on paper, equity is positive at $324.1 million, the report contains no going-concern doubt, and the $495.1 million royalty liability only has to be serviced from HEMGENIX income. That the stock has lost half its value since June 2026 is a question of price, not quality. The next milestones are the advisory committee date and the start of the confirmatory study. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
uniQure is a well-funded gene therapy company with $810.3 million in cash whose Huntington’s therapy AMT-130 has been under FDA review since November 2, 2026 (target date May 1, 2027). The evidence is thin and was disputed within the agency itself, the primary endpoint missed significance after four years, there is hardly any revenue of its own, and the share count has risen 41.6 percent since the end of 2024. At $22.97 (November 2, 2026), cash covers about half of the market value. Not investment advice.
Funding
As of June 30, 2026, uniQure held $810.3 million in cash and current investment securities; according to the quarterly report, that lasts into 2030. Operating cash outflow was $178.0 million in 2025 and $66.8 million in the first half of 2026. Upon approval before September 30, 2027, up to $100 million in additional credit becomes available.
AMT-130 evidence
The application rests on twelve high-dose patients at 36 months compared with an external control from the Enroll-HD database. At 48 months, the primary endpoint cUHDRS missed significance with 44 percent slowing (p=0.144); everyday functioning showed 61 percent (nominal p=0.008).
Regulatory process
The FDA accepted the application with priority review on November 2, 2026, target date May 1, 2027, and an advisory committee is tentatively planned. Before that, it changed its stance on the same data in November 2025, early 2026 and June 2026. Accelerated approval requires a confirmatory study with about 200 patients.
Revenue base
uniQure generated only $16.1 million in 2025 revenue from HEMGENIX royalties against a $199.0 million net loss. In the first half of 2026, $9.4 million in revenue was matched by $9.2 million in payments to the royalty buyer, whose claim runs up to $693.8 million through mid-2032.
Dilution
The share count rose 41.6 percent from December 31, 2024, to July 24, 2026, to 69.37 million, most recently through the June 2026 offering at $45.50. Another 8.04 million potential shares are outstanding; authorized capital was raised to 100 million shares.
Worth Noting
uniQure made our research list through the Reddit hype scanner (mentions in Reddit forums). We reviewed the annual reports (10-K) for 2025 (filed 03/02/2026) and 2024 (02/27/2025), the quarterly reports (10-Q) for 03/31/2026 and 06/30/2026 (07/29/2026), the earnings release (8-K Item 2.02, Exhibit 99.1) of 07/29/2026, and every filing since: S-8 of 07/29/2026, Schedule 13G/13G-A of 08/14 and 10/16/2026 (passive stakes), 8-Ks of 09/02/2026 (U.S. and U.K. applications), 09/29/2026 (four-year data) and 11/02/2026 (BLA acceptance). Last insider filing (Form 4) on 07/07/2026. No 10-Q for 09/30/2026 had been filed as of 11/03/2026.
Our own calculations from reported figures: 69,366,412 shares (07/24/2026) vs. 48,988,087 (12/31/2024) = up 41.6%; 8,039,069 potential shares (06/30/2026) = about 11.6% of shares outstanding; market value 69,366,412 × $22.97 = about $1.593 billion (identical to the fundamental data figure); $1.593 billion minus $810.3 million cash plus the $50.0 million Hercules loan = about $830 million; cash runway $810.3 million / $178.0 million = about 4.5 years at the 2025 pace; CEO sales 06/17–07/02/2026 per Form 4: 262,594 shares, about $12.1 million in total.
Data gaps named openly: no P/E (loss); price-to-sales and Altman Z (fundamental data: −0.6) say little about a research company without product revenue; reporting currency U.S. dollars with many euro obligations, hence currency effects in earnings (2025: +$26.1 million, Q2 2026: −$1.7 million). Risk of confusion: AMT-130 and ifezuntirgene inilparvovec are the same therapy; HEMGENIX is sold by CSL Behring, not uniQure. Analyses are evergreen; daily prices are not a reason to buy.
Stock Watch
This analysis is as of November 3, 2026. Stock Watch will tell you what's changed at QURE since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 9.00 $ to 51.10 $ · Last price: 23.80 $ (As of: November 13, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 11/14/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Uniqure NV QURE | 1.7 | – | 1.4 | -559.9 | -872.2 | -40.6 | -21.5 |
| Vertex Pharmaceuticals Inc VRTX | 136.2 | 32.1 | 27.5 | 54.8 | 38.1 | 9.6 | 24.0 |
| Regeneron Pharmaceuticals Inc REGN | 99.3 | 24.1 | 14.1 | 46.7 | 20.7 | 1.0 | 38.2 |
| Moderna Inc MRNA | 88.6 | – | 4.6 | -66.0 | -131.1 | -39.2 | 794.9 |
| argenx NV ARGX | 59.7 | 36.7 | 27.6 | 59.8 | 32.0 | 89.6 | 7.7 |
| BeiGene, Ltd. ONC | 47.1 | 74.4 | 29.5 | 89.4 | 19.1 | 40.2 | 10.2 |
| Royalty Pharma Plc RPRX | 38.2 | 37.5 | 24.0 | 99.8 | 100.3 | 5.1 | 78.4 |
| Revolution Medicines Inc RVMD | 35.8 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 167.6 |
| Genmab AS GMAB | 32.0 | 40.4 | 28.6 | 92.7 | 35.2 | -82.7 | 69.9 |
| Median of companies shown | 47.1 | 37.1 | 24.0 | 54.8 | 20.7 | 1.0 | 38.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 25 | -72 | -73 | -2.93 | -72 | 64 | 190 |
| 2017 | 13 | -72 | -80 | -2.98 | -64 | 90 | 209 |
| 2018 | 11 | -88 | -83 | -2.34 | -76 | 180 | 274 |
| 2019 | 7 | -121 | -124 | -3.11 | -99 | 323 | 449 |
| 2020 | 38 | -125 | -125 | -2.81 | -135 | 244 | 340 |
| 2021 | 524 | 311 | 330 | 7.04 | 288 | 596 | 809 |
| 2022 | 106 | -143 | -127 | -2.71 | -145 | 476 | 705 |
| 2023 | 16 | -283 | -308 | -6.47 | -146 | 208 | 832 |
| 2024 | 27 | -184 | -240 | -4.92 | -183 | -7 | 557 |
| 2025 | 16 | -188 | -199 | -3.46 | -178 | 199 | 825 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.84 | 52.00 | 2 | 62.50 | -1,940.40 | -37 | -45 |
| 2024: Q4 | -1.50 | 2.00 | 5 | -21.90 | -1,403.20 | -53 | -53 |
| 2025: Q1 | -0.82 | 39.70 | 2 | -81.50 | -2,784.70 | -44 | -44 |
| 2025: Q2 | -0.69 | 40.50 | 5 | -52.70 | -716.80 | -40 | -40 |
| 2025: Q3 | -1.38 | -64.30 | 4 | 61.80 | -2,175.90 | -16 | -17 |
| 2025: Q4 | -0.47 | 68.40 | 6 | 6.60 | -666.10 | -78 | -78 |
| 2026: Q1 | -0.85 | -3.70 | 4 | 127.30 | -1,502.90 | -38 | -38 |
| 2026: Q2 | -1.22 | -76.80 | 6 | 11.00 | -1,387.80 | -29 | -29 |
| 2026: Q3 | -0.88 | 36.20 | 5 | 40.50 | -1,176.90 | -48 | -48 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Momentum & Trend
Research
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.30 | -3.47 – -3.12 | 19 | -12.8% | 8 |
| 12/31/2027 | -2.84 | -3.83 – -0.52 | 112 | 14.0% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Geprüft am 03.11.2026 gegen die Geschäftsberichte (10-K) 2025 (eingereicht 02.03.2026) und 2024 (27.02.2025) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 30.06.2026: In den ausgewerteten SEC-Filings von uniQure findet sich kein wesentlicher KI-Bezug. Die einzigen Erwähnungen von „artificial intelligence“ stehen in einem Compliance-Risikofaktor des 10-K 2025 zu Datenschutz- und KI-Regulierung („We are subject to laws governing data protection and artificial intelligence (“AI”) in the different jurisdictions in which we operate.“ — „Wir unterliegen in den verschiedenen Rechtsordnungen, in denen wir tätig sind, Gesetzen zum Datenschutz und zur künstlichen Intelligenz (KI).“), ergänzt um einen Hinweis auf die Pflichten aus dem EU AI Act. Das ist weder eine KI-Umsatzquelle noch ein belegter operativer KI-Einsatz noch ein konkretes KI-Risiko für das eigene Geschäftsmodell der Gentherapie-Firma (AMT-130 gegen Huntington, Lizenzerlöse aus HEMGENIX); die übrigen fünf Filings enthalten keinen KI-Treffer. Nach dem Kriterienkatalog: neutral.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-07-29 · 10-Q 2026-05-05 · 10-Q 2025-11-10 · 10-Q 2025-07-29 · 10-K 2026-03-02 · 10-K 2025-02-27
Rated on November 3, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -46.7%
- More than 10% revenue growth is expected for the coming year -66.2%
- Share count grows by less than 3% a year 7.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1,148.9%
- Gross margin at 40% or higher and without meaningful erosion 89.5%
- Goodwill from acquisitions does not grow faster than revenue 3.1%
- Net debt below twice EBITDA 86 m net cash
- Operating cash flow covers the profits of the last three years 240 m
- Return on capital at 15% or higher, or up versus two years ago -24.7%
- Insiders hold at least 10% or are net buyers 1.3%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -4.8%
- Exp. sales growth 3Y > 5% 163.8%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 163.8%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -197.5%
- ROCE > 15% -24.6%
- Expected return > 10% 135.3%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | Meek David D. | Director | Sell | 9,080 | 21.25 | 192,950 |
| Oct 30, 2026 | Abi-Saab Walid | Chief Medical Officer | Other | 18,750 | 0.00 | – |
The company
About the Company
uniQure N.V. entwickelt Behandlungen für Patienten, die an seltenen und anderen schweren Erkrankungen leiden, in den Vereinigten Staaten. Das Unternehmen bietet HEMGENIX an, das es Menschen mit Hämophilie B ermöglicht, Faktor IX zu produzieren, wodurch sich das Blutungsrisiko senken lässt. Sein führender Produktkandidat ist AMT-130, ein Gentherapiekandidat, der sich in einer Phase-I/II-Studie zur Behandlung der Huntington-Krankheit befindet. Das Unternehmen entwickelt zudem AMT-260, das sich in einer Phase-I/IIa-Studie zur Behandlung der mesialen Temporallappenepilepsie befindet; AMT-162, das sich in einer Phase-I/IIa-Studie zur Behandlung der Superoxid-Dismutase-Enzym-assoziierten amyotrophen Lateralsklerose befindet; sowie AMT-191, einen experimentellen Gentherapiekandidaten, der sich in einer Phase-I/IIa-Studie zur Behandlung von Morbus Fabry befindet. Es hat eine Lizenzvereinbarung mit Apic Bio zur Entwicklung, Herstellung und Vermarktung einer intrathekal verabreichten experimentellen Gentherapie für ALS, die durch Mutationen in SOD-1 verursacht wird; sowie eine Entwicklungs- und Lieferabkommen mit CLS Behring für die kommerzielle Versorgung. uniQure N.V. wurde 1998 gegründet und hat seinen Hauptsitz in Amsterdam, Niederlande.
- Employees
- 221
- Headquarters
- Amsterdam, Netherlands
- Address
- Paasheuvelweg 25, 1105 BP Amsterdam, Netherlands
- Phone
- 31 20 240 6000
- Website
- uniqure.com
- IPO Date
- 06/20/2007
- ISIN
- NL0010696654
- Stock Split
- 1:5 on 01/31/2014
Management
| Name | Title | Birth Year |
|---|---|---|
| Matthew Craig Kapusta CPA | CEO & Executive Director | 1972 |
| Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 1973 |
| Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1962 |
| Walid Abi-Saab M.D. | Chief Medical Officer | 1965 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | – |
| Amin Abujoub Ph.D. | Chief Technical Operations Officer | – |
| Richard Porter Ph.D. | Chief Business & Scientific Officer | 1968 |
| Chiara Elizabeth Russo | Senior Director of Investor Relations | – |
| Tamara Tugal Ph.D., MBA | Business Development Director | – |
| Erin Boyer | Chief People & Culture Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 11/04/2026 uniQure N.V. (QURE): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 11/02/2026 uniQure N.V. (QURE): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
- 09/29/2026 uniQure N.V. (QURE): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 09/02/2026 uniQure N.V. (QURE): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.